That's a big question. There are many sources of information.
Canada’s Drug Agency recently did some work on patient registries through the national strategy for drugs for rare diseases. There's a lot of rich registry data that's available on patient outcomes. We can see where drugs have been in shortage and where they might affect patient outcomes in some aspects.
I think it's a collaboration. I think there's a leadership role here for the federal government. Our provinces and territories all have their own systems. Through the health care agreements that we have in place, in terms of some of the bilateral agreements, there's a lot of good stuff going on, but we have to continue to work collaboratively and all shine and do the work we're meant to do.
One of the big challenges that we face is that there's not always great integration between our systems. These registries—some of them, like ours, are 50 years old—are not tapped into. There's a lot of data that we just aren't leveraging in this country.